🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "major milestone" in the fight against superbug strains of the bacteria, according to health experts.

An International Challenge

Gonorrhoea infections are on the rise globally, with estimates suggesting over 82 million infections annually. Especially elevated rates are reported in the African continent and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the face of growing infection rates, escalating drug resistance and the very limited therapeutic options at this time.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program found that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Receive Authorization

Zoliflodacin, alternatively called a brand name, was authorized by the US FDA in December for treating gonorrhoea. This STI can lead to significant complications, including infertility. Experts believe that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, gained clearance in close succession. This drug, which is also used to treat UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to develop it.

“This authorization marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Clinical Trial Data and Global Access

According to data published in a major medical journal, the new drug cured more than 90% of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which combines two antibiotics. The research involved over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the ability to register and commercialise the drug in many regions with limited resources.

Clinicians directly involved have voiced hope. Having a single-dose, oral treatment like this is seen as a "game-changer" for gonorrhoea control. This is deemed essential to alleviate the strain of the disease for individuals and to stop the proliferation of extremely resistant gonorrhoea worldwide.